Study of URC102 to Assess the Safety and Efficacy in Gout Patients

JW Pharmaceutical76 enrolled

Overview

The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Gout Hyperuricemia

Interventions

URC102DRUG

PlaceboDRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with gout Exclusion Criteria: * Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)

Locations (1)

JW Pharmaceutical

Seoul, Seocho-dong, South Korea

Outcomes

Primary Outcomes

Trend of serum uric acid reduction rate (%)

Time frame: 2 weeks

Trend of serum uric acid levels (mg/dL)

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.